# Edward Mott

> Edward Mott is a funding round investor at Oxford Capital backing Biotechnology and Medical. See 12 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Oxford Capital](https://shizune.co/investors/profile/oxford-capital-partners)
- Location: Oxford, United Kingdom
- Total investments: 12
- Last investment: Feb 2015
- Lead investor: 25%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/pub/edward-ted-mott/1b/333/739

Edward Mott is a funding round investor at Oxford Capital in Oxford focused on Biotechnology and Medical. Edward co-founded Oxford Capital in 1999 with the intent of broadening the access to private equity to wealthy families and corporations around the world as well as to institutional investors. He chairs the Investment Committee at Oxford Capital. With over 30 years of experience as a business leader, practical manager, investor and companydirector, Ted has worked with both mature listed businesses and younger high growth companies across a multitude of sectors. He has also been actively involved in a wide range of infrastructure projects. Following an early career in the US with Corning Glass Inc. where he was involved with the first commercialisation of fibre optics, he then pursued a career in investment banking with American, European and Asian banks in corporate finance, emerging markets and structured finance, before heading HSBC’s capital markets division based in Hong Kong. He later served the wealth manager GAM in London with responsibility for both institutional and private clients before founding Oxford Capital. Ted is a graduate of the University of Cambridge and an INSEAD MBA and is fluent in French and German. Ted is also a keen sailor and gardener.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 25% |
| Medical | 1 | 8% |
| Chemical | 1 | 8% |
| Genetics | 1 | 8% |
| Agriculture | 1 | 8% |

11 industries tracked in total.

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Microbial Solutions | Microbial Solutions Limited offers a technology that can provide on-site treatment and disposal of MWFs which can unlock and release the replacement value of both the existing treatment technology and the associated logistics costs. The Microcycle™ technology is a powerful, patented biological degradation process that reduces waste MWFs toacceptable COD concentrations, removes toxicity and allows for the safe disposal of MWF as grey water to sewers on site. Through their offering, Microbial Solutions seeks to help their clients to cost-effectively meet their environmental responsibilities and to provide regulators with the tools to implement the regulations enshrining those responsibilities. | $655K |  | Feb 13, 2015 |  |
| Exosect | Exosect was established in 2001 as a spin-out from the University of Southampton to develop a platform technology and range of natural bio-control products for the protection of food from pests and disease. Having developed the technology, gained 41 patents and 28 national product registrations and successfully test-marketed the technology andproducts, the Company is well-positioned to commercialise its unique patented platform technology across the food supply chain. | $2.1M |  | Jan 16, 2015 |  |
| Oxitec | Oxitec is developing and commercialising an effective and environment-friendly proprietary technology for the control of significant insect pests. Oxitec’s technology has the potential to make a major contribution for both global health and agriculture by combating insects responsible for serious diseases such as dengue fever as well asagricultural damage. The proprietary technology builds on inventions from the University of Oxford and employs genetics and molecular biology to enhance the cost-effectiveness and safety of the existing Sterile Insect Technique (SIT), and to extend SIT to a broader range of insect pests. | $10M |  | Jun 24, 2014 |  |
| Exosect | Exosect was established in 2001 as a spin-out from the University of Southampton to develop a platform technology and range of natural bio-control products for the protection of food from pests and disease. Having developed the technology, gained 41 patents and 28 national product registrations and successfully test-marketed the technology andproducts, the Company is well-positioned to commercialise its unique patented platform technology across the food supply chain. | $3.3M |  | May 28, 2013 |  |
| Exosect | Exosect was established in 2001 as a spin-out from the University of Southampton to develop a platform technology and range of natural bio-control products for the protection of food from pests and disease. Having developed the technology, gained 41 patents and 28 national product registrations and successfully test-marketed the technology andproducts, the Company is well-positioned to commercialise its unique patented platform technology across the food supply chain. |  |  | Nov 02, 2012 |  |
| Oxitec | Oxitec is developing and commercialising an effective and environment-friendly proprietary technology for the control of significant insect pests. Oxitec’s technology has the potential to make a major contribution for both global health and agriculture by combating insects responsible for serious diseases such as dengue fever as well asagricultural damage. The proprietary technology builds on inventions from the University of Oxford and employs genetics and molecular biology to enhance the cost-effectiveness and safety of the existing Sterile Insect Technique (SIT), and to extend SIT to a broader range of insect pests. | $10.5M |  | Feb 14, 2012 |  |
| Exosect | Exosect was established in 2001 as a spin-out from the University of Southampton to develop a platform technology and range of natural bio-control products for the protection of food from pests and disease. Having developed the technology, gained 41 patents and 28 national product registrations and successfully test-marketed the technology andproducts, the Company is well-positioned to commercialise its unique patented platform technology across the food supply chain. | $1.8M |  | Jan 18, 2012 |  |
| Exosect | Exosect was established in 2001 as a spin-out from the University of Southampton to develop a platform technology and range of natural bio-control products for the protection of food from pests and disease. Having developed the technology, gained 41 patents and 28 national product registrations and successfully test-marketed the technology andproducts, the Company is well-positioned to commercialise its unique patented platform technology across the food supply chain. | $1M |  | Oct 14, 2011 |  |
| Oxitec | Oxitec is developing and commercialising an effective and environment-friendly proprietary technology for the control of significant insect pests. Oxitec’s technology has the potential to make a major contribution for both global health and agriculture by combating insects responsible for serious diseases such as dengue fever as well asagricultural damage. The proprietary technology builds on inventions from the University of Oxford and employs genetics and molecular biology to enhance the cost-effectiveness and safety of the existing Sterile Insect Technique (SIT), and to extend SIT to a broader range of insect pests. | $4.6M |  | Mar 29, 2011 |  |
| Oxford BioTherapeutics | Oxford BioTherapeutics (OBT) is focused on the development of targeted medicines in the field of cancer. The company has signed strategic partnerships with the leading antibody companies Medarex, Biosite and Amgen to build a broad pipeline of novel antibody therapeutics using its unique OGAP® (Oxford Genome Anatomy Project) platform. OGAP® is oneof the world’s largest proprietary human protein databases which contains and combines proteomic and genomic data with related clinical information. OBT also intends to develop companion diagnostics for selected antibody programmes. The company expects to improve disease management and treatment outcomes by integrating diagnostics into product development and commercialisation activities. | $902K |  | Aug 20, 2010 |  |

10 of 12 investments shown.

## Co-investors
- [Alpina Partners](https://shizune.co/investors/profile/alpina-partners) — VC Fund, 4 deals together
- [Entrepreneurs Fund](https://shizune.co/investors/profile/entrepreneurs-fund) — VC Fund, 4 deals together
- [South East Growth Fund & Management](https://shizune.co/investors/profile/south-east-growth-fund-management) — VC Fund, 2 deals together
- [Catapult Ventures](https://shizune.co/investors/profile/catapult-venture-managers) — VC Fund, 1 deal together
- [H2O Venture Partners](https://shizune.co/investors/profile/h2o-venture-partners) — VC Fund, 1 deal together
- [UK Innovation & Science Seed Fund](https://shizune.co/investors/profile/rainbow-seed-fund) — VC Fund, 1 deal together

## About Oxford Capital

VC Fund · Oxford, United Kingdom

Oxford Capital is an experienced technology venture capital investor based in London and Oxford. They focus on investing in a diversified portfolio of high-potential pure technology and technology-enabled start-up businesses.

5 contacts available at Oxford Capital.

| Name | Title | Profile |
| --- | --- | --- |
| Chris Payne | Investor | https://shizune.co/investors/profile/chris-payne-92ee |
| David Mott | Founder Partner | https://shizune.co/investors/profile/david-mott-2 |
| Edward Mott | Chairman | https://shizune.co/investors/profile/edward-mott |
| James Witter | Non-Executive Director | https://shizune.co/investors/profile/james-witter |
| Richard Roberts | Director, Investor Relations | https://shizune.co/investors/profile/richard-roberts-2 |

## Similar investors

### Similar stage
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [HTGF (High-Tech Gruenderfonds)](https://shizune.co/investors/profile/high-tech-gr%C3%BCnderfonds) — VC Fund

## FAQ

### What does Edward Mott invest in?

Edward Mott invests primarily in Biotechnology, Medical and Chemical startups, most often at Funding Round stage. Most of the 12 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Edward Mott last invest?

The most recent investment recorded for Edward Mott closed in Feb 2015. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co